How to calculate number of samples in the design of pre/pro-biotics studies (metagenomic studies)

Podeu consultar el III Workshop anual INSA-UB complet a: http://hdl.handle.net/2445/118993Sessió 2. Pòster núm. 2

Hybrid Ionic Liquid-Chitosan Membranes for CO2 Separation: Mechanical and Thermal Behavior

Pure chitosan (CS) and hybrid ionic liquid-chitosan membranes loaded with 5 wt% 1-ethyl-3-methylimidazolium acetate ([emim][Ac]) ionic liquid were prepared in order to improve the thermal behavior of supported ionic liquidmembranes (SILMs) for CO2 separation. Gas permeability, solubility and diffusivity were evaluated in the temperature range 298-323 K. The temperature influence was well described in terms of the Arrhenius-van't Hoff exponential relationships. Activation energies were calculated and comparedwith those obtained for SILMs with the same ionic liquid. The introduction of this ionic liquid in the hybrid solid membrane decreases the permeability activation energy, leading to a lower influence of the temperature in the permeability and diffusivity. Moreover, the thermal behavior is similar to pure chitosan membranes, and the mechanical strength and flexibility were improved due to the introduction of the ionic liquid in the polymer matrixFinancial support from the Spanish Ministry of Economy and Competitiveness (MINECO) under projects ENE 2010–14828 and CTQ2012-31229 is gratefully acknowledged. C.C.C. also thanks the Ministry for the Ramón y Cajal grant (RYC-2011-08550) at the Universidad de Cantabria

OSTVARENJE URAVNOTEŽENOG PRISTUPA IZMEĐU ŽRTVE I PRIJESTUPNIKA: INTEGRIRANJE PROAKTIVNOG PRISTUPA PREMA ŽRTVI

The Mediation and Reparation Program (MRP) was from the outset set up with the mission of serving both victims’ and offenders’ needs alike, that is to say, informed by a balanced approach between victim and offender in accordance with the restorative justice (RJ) principles. Concerned with the risk of secondary victimisation, the scheme has traditionally observed the protective approach; therefore as a general rule, with serious crimes we have followed the offender-initiated model. However, the experience gathered has shown that such practice was not fully in line with our stated mission as victims were having more limited access to the scheme compared to offenders. The aim of this paper is to share the process that has led a team of practitioners to reflect on our practice and review the protective approach in place. To that end, the combination of factors we have identified to be at the root of this transformation will be analysed, and the key changes introduced in order to improve victims’ access will also be outlined.Program posredovanja (medijacije) i reparativne pravde od samoga je početka pokrenut s misijom jednakomjernog služenja potrebama žrtava i počinitelja, odnosno, utemeljen je na uravnoteženom pristupu između žrtve i počinitelja, u skladu s načelima restorativne pravde. Zaokupljen rizikom od sekundarne viktimizacije, program kao i uvijek slijedi načela zaštitničkog pristupa; stoga smo, kao opće pravilo, kod teških zločina slijedili model koji se pokreće na zahtjev počinitelja. No prikupljeno je iskustvo pokazalo da takva praksa nije sasvim u skladu s našom misijom jer su žrtve, u usporedbi s počiniteljima, imale ograničeniji pristup programu. Cilj ovoga rada je predstavljanje procesa koji je skupinu praktičara navodio na razmišljanje o našoj praksi i pregledavanje ustanovljenog zaštitničkog pristupa. U tu će se svrhu analizirati kombinacija čimbenika za koje smo identificirali da se nalaze u korijenu takve transformacije, te će se također navesti ključne promjene koje su uvedene kako bi se žrtvama olakšao pristup

Chitosan feasibility to retain retinal stem cell phenotype and slow proliferation for retinal transplantation

Retinal stem cells (RSCs) are promising in cell replacement strategies for retinal diseases. RSCs can migrate, differentiate, and integrate into retina. However, RSCs transplantation needs an adequate support; chitosan membrane (ChM) could be one, which can carry RSCs with high feasibility to support their integration into retina. RSCs were isolated, evaluated for phenotype, and subsequently grown on sterilized ChM and polystyrene surface for 8 hours, 1, 4, and 11 days for analysing cell adhesion, proliferation, viability, and phenotype. Isolated RSCs expressed GFAP, PKC, isolectin, recoverin, RPE65, PAX-6, cytokeratin 8/18, and nestin proteins. They adhered (28 ± 16%, 8 hours) and proliferated (40 ± 20 cells/field, day 1 and 244 ± 100 cells/field, day 4) significantly low on ChM. However, they maintained similar viability (>95%) and phenotype (cytokeratin 8/18, PAX6, and nestin proteins expression, day 11) on both surfaces (ChM and polystyrene). RSCs did not express alpha-SMA protein on both surfaces. RSCs express proteins belonging to epithelial, glial, and neural cells, confirming that they need further stimulus to reach a final destination of differentiation that could be provided in in vivo condition. ChM does not alternate RSCs behaviour and therefore can be used as a cell carrier so that slow proliferating RSCs can migrate and integrate into retina

Un diccionario de colocaciones en latín (II): su aplicación a la traducción de textos.

Depto. de Filología ClásicaFac. de FilologíaFALSEsubmitte

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although ADT is initially effective, a subsequent castration resistance status (CRPC) is commonly developed. The expression of androgen receptor (AR) alternative splicing isoforms (AR-V7 and AR-V9) has been associated to CRPC. However, resistance mechanisms to novel NHAs are not yet well understood. Androgen-dependent PCa cell lines were used to generate resistant models to ADT only or in combination with Abiraterone and/or Enzalutamide (concomitant models). Functional and genetic analyses were performed for each resistance model by real-time cell monitoring assays, flow cytometry and RT-qPCR. In androgen-dependent PCa cells, the administration of Abiraterone and/or Enzalutamide as first-line treatment involved a critical inhibition of AR activity associated with a significant cell growth inhibition. Genetic analyses on ADT-resistant PCa cell lines showed that the CRPC phenotype was accompanied by overexpression of AR full-length and AR target genes, but not necessarily AR-V7 and/or AR-V9 isoforms. These ADT resistant cell lines showed higher proliferation rates, migration and invasion abilities. Importantly, ADT resistance induced cross-resistance to Abiraterone and/or Enzalutamide. Similarly, concomitant models possessed an elevated expression of AR full-length and proliferation rates and acquired cross-resistance to its alternative NHA as second-line treatment.Instituto de Salud Carlos III PI17/00989European Regional Development Fund "A way to build Europe"Ramon y Cajal - Ministry of Economy and Competitiveness RYC-2015-18382Ministry of Education, Culture and Sport FPU14/05461University of Granad

Lichens and lichenicolous fungi of Serranía de Ronda (Málaga-Cádiz), southern Spain

As a result of a field trip organised by the Spanish Lichen Society in Serranía de Ronda, south Spain, a catalogue of 360 taxa is presented (336 lichens, 24 lichenicolous fungi). The list includes three new records for the Iberian Peninsula: Arthonia paretinaria, Micarea myriocarpa and Niesslia keissleri, 51new ones for the Autonomous Andalusian Community, and three and 81 new ones for the province of Cádiz and of Málaga, respectively. After these results, the total updated number of the province of Málaga rises to 556 lichens and lichenicolous fungi. The best represented lichen genus is Cladonia (18) with the most species, unlike Lecanora (15), Pertusaria (12), Physconia (12) and Collema (9). As regard habitat, most lichen species are mainly corticolous (55%), as opposed to saxicolous (24%), terricolous (14%) as the species growing on other lichens as lichenicolous fungi (7%). The percentages of lichen growth forms are mainly foliose (50%) and crustose (31%), while fruticose (7%), crustose squamulose (6%) and dimorphic (6%) are less represented. The lichen with a green photobiont (Chlorophyta 84%) predominates, while the cyanobacteria photobiont (15%) is less represented

Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster

The humoral immune response developed after receiving the full vaccination schedule against COVID-19 is impaired in individuals who received anti-CD20 therapy 6-9 months before vaccination. However, there is little information about the cellular immune responses elicited in these individuals. In this study, we analyzed the humoral and cellular immune responses in 18 individuals with hematological disease who received the last dose of rituximab 13.8 months (IQR 9.4-19) before the booster dose. One month after receiving the booster dose, the seroconversion rate in the rituximab-treated cohort increased from 83.3% to 88.9% and titers of specific IgGs against SARS-CoV-2 increased 1.53-fold (p = 0.0098), while the levels of neutralizing antibodies increased 3.03-fold (p = 0.0381). However, the cytotoxic activity of peripheral blood mononuclear cells (PBMCs) from rituximab-treated individuals remained unchanged, and both antibody-dependent cellular cytotoxicity (ADCC) and direct cellular cytotoxicity (CDD) were reduced 1.7-fold (p = 0.0047) and 2.0-fold (p = 0.0086), respectively, in comparison with healthy donors. Breakthrough infections rate was higher in our cohort of rituximab-treated individuals (33.33%), although most of the infected patients (83.4%) developed a mild form of COVID-19. In conclusion, our findings confirm a benefit in the humoral, but not in the cellular, immune response in rituximab-treated individuals after receiving a booster dose of an mRNA-based vaccine against COVID-19.This work was supported by the Strategic Action in Health 2017–2020 of the Instituto de Salud Carlos III (PI21/00877), by the Coordinated Research Activities at the National Center of Microbiology (CNM, Instituto de Salud Carlos III) (COV20_00679) to promote an integrated response against SARS-CoV-2 in Spain (Spanish Ministry of Science and Innovation) that is coordinated by Dr Inmaculada Casas (WHO National Influenza Center of the CNM), and by a generous donation provided by Chiesi España, S.A.U. (Barcelona, Spain). The work of Montserrat Torres is financed by the Hematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal (Madrid, Spain). The work of Sara Rodríguez-Mora is financed by NIH grant R01AI143567. The work of Guiomar Casado is financed by CIBERINFEC, co-financed by the European Regional Development Fund (FEDER) “A way to make Europe”. The work of Fernando Ramos-Martín is financed by the Spanish Ministry of Science and Innovation (PID2019-110275RB-I00).S

La base de datos COLAT (I): las colocaciones verbo-nominales en la docencia de la lengua latina

Depto. de Filología ClásicaFac. de FilologíaFALSEsubmitte

La Base de Datos COLAT (II) y su aplicación docente: colocaciones y construcciones con verbo soporte en latín (memoria del proyecto)

Depto. de Filología ClásicaFac. de FilologíaFALSEsubmitte